Hydrogen (H2) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways.
Yaxing Zhang, Jingting Xu, Zhiyuan Long, Chen Wang, Ling Wang, Peng Sun, Ping Li, Tinghuai Wang · Frontiers in pharmacology · 2016
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, intraperitoneal injection of H₂ prevented cardiac hypertrophy and improved cardiac function in ISO-infused mice. These results are preclinical and suggest molecular hydrogen's therapeutic potential in the condition studied. Further human research is needed to establish clinical effectiveness.
What the Researchers Studied
The goal of the present study is to determine the pharmacodynamics of H₂ in a model of isoproterenol (ISO)-induced cardiac hypertrophy.
How Molecular Hydrogen Was Used
Mice received H₂ (1 ml/100g/day, intraperitoneal injection) for 7 days before ISO (0.5 mg/100g/day, subcutaneous injection) infusion, and then received ISO with or without H₂ for another 7 days.
What the Researchers Found
Intraperitoneal injection of H₂ prevented cardiac hypertrophy and improved cardiac function in ISO-infused mice. H₂ blocked the excessive expression of NADPH oxidase and the accumulation of ROS, attenuated the decrease of MMP, and inhibited ROS-sensitive ERK1/2, p38, and JNK signaling pathways.
H₂ Mechanisms / Biological Findings
And Purpose: Hydrogen (H₂) has been shown to have a strong antioxidant effect on preventing oxidative stress-related diseases.
Authors’ Conclusion
The authors concluded that H₂ inhibits ISO-induced cardiac/cardiomyocytes hypertrophy both in vivo and in vitro, and improves the impaired left ventricular function.